Trials / Terminated
TerminatedNCT05144347
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.
Conditions
- Non-Hodgkin's Lymphoma (NHL)
- Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL114 | Tablets of XL114 |
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2021-12-03
- Last updated
- 2023-07-11
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05144347. Inclusion in this directory is not an endorsement.